Short Interest in DaVita Inc. (NYSE:DVA) Decreases By 14.2%

DaVita Inc. (NYSE:DVA) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 6,943,051 shares, a decline of 14.2% from the December 31st total of 8,092,541 shares. Based on an average daily volume of 975,529 shares, the days-to-cover ratio is presently 7.1 days. Currently, 10.0% of the company’s shares are sold short. Currently, 10.0% of the company’s shares are sold short. Based on an average daily volume of 975,529 shares, the days-to-cover ratio is presently 7.1 days.

More DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 results beat estimates — DaVita reported Q4 EPS above consensus and revenue of $3.62B (≈+9.9% YoY), a core driver of the move higher. DaVita Inc. 4th Quarter 2025 Results
• Positive Sentiment: FY‑2026 guidance raised — Management set FY‑2026 EPS at $13.60–$15.00, above the street’s prior consensus (~$12.80), signaling confidence in steady dialysis demand and driving upside re‑pricing. DaVita forecasts 2026 profit above estimates
• Positive Sentiment: Market reaction: shares jumped after hours — Media coverage and after‑hours trading showed a clear positive reaction to the beat + guide combination. Stocks making the biggest moves after hours
• Neutral Sentiment: Underlying operating trends mixed but generally improving — revenue, gross profit and operating profit grew YoY, supporting the raised guide; investors will watch margin sustainability. DaVita Q4 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: Earnings call flagged challenges — management highlighted headwinds and execution items in the call; the market is balancing the brighter outlook against those operational risks. DaVita Q4 2025 Earnings Call Highlights
• Negative Sentiment: Some profit and cash-flow caveats — reported net income attributable fell YoY and cash & cash equivalents declined while total liabilities increased, which could concern value‑oriented investors. DaVita Q4 financial detail summary
• Negative Sentiment: Institutional selling and mixed analyst stance — recent filings show large holders trimming positions (notably Berkshire reductions last year) and at least one underperform rating remains, which could limit further multiple expansion. Institutional holdings and analyst context

DaVita Price Performance

NYSE DVA traded up $24.92 during trading on Tuesday, reaching $136.11. 2,063,569 shares of the company’s stock traded hands, compared to its average volume of 1,038,307. DaVita has a 12-month low of $101.00 and a 12-month high of $178.47. The firm has a market cap of $9.61 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 0.67 and a beta of 0.99. The company’s 50 day simple moving average is $113.42 and its two-hundred day simple moving average is $124.86.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The company’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts expect that DaVita will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the topic of a number of analyst reports. Truist Financial cut their price objective on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Barclays increased their price objective on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research report on Tuesday. TD Cowen restated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Finally, UBS Group reiterated a “buy” rating on shares of DaVita in a report on Monday, December 15th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $148.60.

Institutional Investors Weigh In On DaVita

A number of hedge funds have recently made changes to their positions in the stock. Elevation Wealth Partners LLC grew its stake in DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after purchasing an additional 165 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in shares of DaVita during the 2nd quarter worth approximately $36,000. Canada Pension Plan Investment Board purchased a new stake in DaVita during the second quarter valued at approximately $43,000. Finally, iSAM Funds UK Ltd acquired a new stake in DaVita in the third quarter valued at approximately $46,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.